Acesion Pharma Raises 15.2M DKK
Dec 17, 2014December 17, 2014 Acesion Pharma raises 15.2 million DKK in new equity from Novo A/S and Broadview Ventures.
Acesion Pharma, a Danish biotech company developing novel therapeutic treatment for atrial fibrillatin (AF), today announced that it has raised 15.2 million DKK (2.5 million USD) in a new equity investment round. The round included Boston-based Broadview Ventures as a new investor and current investor Novo Seeds.